| Patents for A61P 25 - Drugs for disorders of the nervous system (183,225) |
|---|
| 05/26/2011 | US20110124661 Oxazolobenzimidazole derivatives |
| 05/26/2011 | US20110124659 Cycloalkane derivative |
| 05/26/2011 | US20110124658 Substituted oxindole derivatives and their use as vasopressin receptor ligands |
| 05/26/2011 | US20110124657 Method for screening of 5ht7 receptor ligands based on a new pharmacophore model and a descriptor's profile filter |
| 05/26/2011 | US20110124656 Methods and Compositions for Treating Symptoms Associated with Post-Traumatic Stress Disorder using Cyclobenzaprine |
| 05/26/2011 | US20110124653 Aryl-sulphonamidic dimers as metalloproteases inhibitors |
| 05/26/2011 | US20110124642 Potassium channel modulators |
| 05/26/2011 | US20110124641 Benzothiazole kinase inhibitors and methods of use |
| 05/26/2011 | US20110124636 2-aza-bicyclo[3.1.0]hexane derivatives as orexin receptor antagonists |
| 05/26/2011 | US20110124634 Bioactive compounds for treatment of cancer and neurodegenerative diseases |
| 05/26/2011 | US20110124631 Treatment of cognitive disorders with certain alpha-7 nicotinic acid receptors in combination with acetylcholinesterase inhibitors |
| 05/26/2011 | US20110124629 Crystalline Forms of a Pharmaceutical Compound |
| 05/26/2011 | US20110124626 Benzazepine derivatives and their use as histamine h3 antagonists |
| 05/26/2011 | US20110124617 Combination Therapy for BreastCancer Comprising an Antiestrogenic Agent |
| 05/26/2011 | US20110124614 Methods And Compositions For The Treatment of Autoimmune Disorders |
| 05/26/2011 | US20110124611 Methods of hormonal treatment utilizing contraceptive regimens with continuous estrogen administration |
| 05/26/2011 | US20110124604 Phospholipid receptors as targets for enhancing drug permeability to selected tissues |
| 05/26/2011 | US20110124601 Aminophosphinic derivatives that can be used in the treatment of pain |
| 05/26/2011 | US20110124600 Use of Dopamine partial agonists for treament of the restless leg syndrome and corresponding pharmaceutical preparation |
| 05/26/2011 | US20110124572 Syndecan-4 is a regulator of rac1-gtp |
| 05/26/2011 | US20110124571 Opiorphin peptide derivatives as potent inhibitors of enkephalin-degrading ectopeptidases |
| 05/26/2011 | US20110124561 Use of a neuregulin to treat peripheral nerve injury |
| 05/26/2011 | US20110124559 Novel compounds as antagonists or inverse agonists at opioid receptors |
| 05/26/2011 | US20110123654 Synergistic enhancement of cellular ergogenic nutrient uptake, like creatine or carnitine, with tarragon |
| 05/26/2011 | US20110123646 Extracts Obtained from Cell Line Cultures from Plants Belonging to the Oleaceae Family (e.g. Syringa Vulgaris), Their Preparation and Use |
| 05/26/2011 | US20110123639 Compound for improving brain functioning and/or treatment of brain disorders |
| 05/26/2011 | US20110123624 Formulations comprising aminosterols |
| 05/26/2011 | US20110123619 Buccal delivery system |
| 05/26/2011 | US20110123618 Controlled release formulation of lamotrigine |
| 05/26/2011 | US20110123593 Self-fixating scaffolds |
| 05/26/2011 | US20110123553 Use of LINGO-4 Antagonists in the Treatment of Conditions Involving Demyelination |
| 05/26/2011 | US20110123551 Hvem/btla, hvem/cd 160 and hvem/gd cis complexes and methods of use |
| 05/26/2011 | US20110123544 Human antibodies that bind human il-12 and methods for producing |
| 05/26/2011 | US20110123541 Human Monoclonal Nicotine Specific Antibodies |
| 05/26/2011 | US20110123538 Composition comprising expression or activity inhibitors of ninjurin 1 for the prevention and treatment of inflammatory disease |
| 05/26/2011 | US20110123535 Use of Nogo Receptor-1 (NGR1) for Promoting Oligodendrocyte Survival |
| 05/26/2011 | US20110123517 Dissolvable pharmaceutical implant |
| 05/26/2011 | US20110123512 Method of regulating the heat shock response |
| 05/26/2011 | US20110123507 Ultra Low Dose Nutraceutical Compositions for Enhancing Sleep Quality and Treating Sleep Disorders |
| 05/26/2011 | US20110123505 Method of producing reduced coenzyme q10 and method of stabilizing the same |
| 05/26/2011 | US20110123499 Cellular differentiation promotion |
| 05/26/2011 | US20110123482 Methods of Treating Neurological Autoimmune Disorders with Cyclophosphamide |
| 05/26/2011 | US20110123466 Pharmaceutical and/or cosmetic composition containing an active principle activator of cytochrome c |
| 05/26/2011 | US20110123449 Solid Forms of N-(4-(7-Azabicyclo[2.2.1]Heptan-7-yl)-2-Trifluoromethyl)Phenyl)-4-Oxo-5-(Trifluoromethyl)-1,4-Dihydroquinoline-3-Carboxamide |
| 05/26/2011 | US20110123436 Dock-and-Lock (DNL) Complexes for Delivery of Interference RNA |
| 05/26/2011 | DE102009054302A1 Chinazolinderivate Quinazoline derivatives |
| 05/26/2011 | CA2781032A1 Ifny inhibitors in the treatment of motoneuron diseases |
| 05/26/2011 | CA2779860A1 Methods and compositions for the treatment of psychotic disorders through the identification of the sult4a1-1 haplotype |
| 05/26/2011 | CA2776855A1 Pharmaceutical composition comprising propofol |
| 05/26/2011 | CA2774868A1 Novel arylated camphenes, processes for their preparation and uses thereof |
| 05/26/2011 | CA2773409A1 Bicyclic compounds as .alpha.4.beta.2 nicotinic acetylcholine receptor ligands |
| 05/25/2011 | EP2325651A2 Compositions and methods for stabilizing transthyretin and inhibiting transthyretin misfolding |
| 05/25/2011 | EP2325317A1 Receptor nucleic acids and polypeptides |
| 05/25/2011 | EP2325315A1 Compositions and methods for inhibiting expression of huntingtin gene |
| 05/25/2011 | EP2325209A2 Improved protofibril selective antibodies and the use thereof |
| 05/25/2011 | EP2325203A2 Cadherin materials and methods |
| 05/25/2011 | EP2325198A1 Compositions and methods for the therapeutic use of an atonal-associated sequence |
| 05/25/2011 | EP2325179A1 Glycosidase ihhibitors and preparation thereof |
| 05/25/2011 | EP2325174A1 Sigma receptor inhibitors |
| 05/25/2011 | EP2324855A1 Hapten-carrier conjugates for treating and preventing nicotine addiction |
| 05/25/2011 | EP2324851A1 Methods of administering anti-TNFalpha antibodies |
| 05/25/2011 | EP2324843A1 Use of TNF-alpha inhibitors for treating nerve root injury |
| 05/25/2011 | EP2324840A1 Production of caffeoylquinic acids from plant cell cultures of echinacea angustifolia |
| 05/25/2011 | EP2324839A1 Identification and use of human bone marrow-derived endothelial progenitor cells to improve myocardial function after ischemic injury |
| 05/25/2011 | EP2324838A1 Compositions Comprising Dimethyl Sulfoxide (DMSO) |
| 05/25/2011 | EP2324834A2 Methods of Increasing Endogenous Erythropoietin (EPO) |
| 05/25/2011 | EP2324830A1 Process for the preparation of a monocyclic azole derivative that inhibits the interaction of ligands with rage |
| 05/25/2011 | EP2324828A1 Treatment for neurodegenerative conditions |
| 05/25/2011 | EP2324825A1 Aryl ureas with angiogenesis inhibiting activity |
| 05/25/2011 | EP2324824A2 Medical application of lipid derivatives of dopamine |
| 05/25/2011 | EP2324035A1 Substituted n-phenyl-2,3-dihydroimidazo[2,1-b]thiazole-5-sulfonamide derivatives as 5-ht6 ligands |
| 05/25/2011 | EP2324032A2 Inhibitors of beta-secretase |
| 05/25/2011 | EP2324021A1 Diazaindole derivatives and their use in the inhibition of c-jun n-terminal kinase |
| 05/25/2011 | EP2324019A1 A crystalline form of 4-(5-{(ir)-1-[5- (3-chlorophenyl) isoxazol-3-yl]ethoxy}-4-methyl-4h-1,2,4-triazol-3-yl) pyridine |
| 05/25/2011 | EP2324017A2 INHIBITORS OF 11beta-HYDROXYSTEROID DEHYDROGENASE 1 |
| 05/25/2011 | EP2324015A2 Thiophene-2-carboxamide derivatives, preparation thereof and therapeutic use thereof |
| 05/25/2011 | EP2324014A2 Silent desensitizers of neuronal nachr and methods of use thereof |
| 05/25/2011 | EP2324013A1 Substituted-quinoxaline-type bridged-piperidine compounds and the uses thereof |
| 05/25/2011 | EP2324007A1 Triazole derivatives and their use as nicotinic acetylcholine receptor modulators |
| 05/25/2011 | EP2323998A1 Aryl-sulphonamidic dimers as metalloproteases inhibitors |
| 05/25/2011 | EP2323988A1 Alpha7 nicotinic acetylcholine receptor inhibitors |
| 05/25/2011 | EP2323971A1 Salicylamide derivatives as nicotinic alpha 7 modulators |
| 05/25/2011 | EP2323735A1 Substituted pyridoxine-lactam carboxylate salts |
| 05/25/2011 | EP2323734A1 Cyclopropylchromene derivatives as modulators of the alpha-2c receptor |
| 05/25/2011 | EP2323692A1 Hangover relief by compositions comprising oral rehydration solution |
| 05/25/2011 | EP2323691A2 Treatment of amyotrophic lateral sclerosis by nogo-a-antagonist |
| 05/25/2011 | EP2323687A2 Method of upregulating sorla for the treatment of alzheimer's disease |
| 05/25/2011 | EP2323680A2 Proteins for use in diagnosing and treating infection and disease |
| 05/25/2011 | EP2323667A1 Modulation of transthyretin expression for the treatment of cns related disorders |
| 05/25/2011 | EP2323658A1 A new crystalline form of 4-(5-{ (ir)-1-[5-(3- chlorophenyl) isoxazol-3-yl]ethoxy}-4-methyl-4h-l, 2, 4-triazol-3-yl) pyridine |
| 05/25/2011 | EP2323649A2 Treating various disorders with 7,8-dihydroxyflavone and derivatives thereof |
| 05/25/2011 | EP2323645A1 Use of low-dose local anaesthetic or derivatives thereof for therapy of chronic pain, especially migraine |
| 05/25/2011 | EP2323640A2 Methods and compositions for treating neuronal damage and modulating transient receptor potential channels |
| 05/25/2011 | EP2323486A1 Methods and compositions for preventing, reducing, or treating damage caused by ischemia and ischemia-like conditions |
| 05/25/2011 | EP2323482A1 Substituted dihydroisoquinolinone and isoquinolinedione derivatives as calcium channel blockers |
| 05/25/2011 | EP2212297B1 Inhibitors of protein kinases |
| 05/25/2011 | EP2056818B1 Compositions and methods for neuroprotection |
| 05/25/2011 | EP1919304B1 Compositions and methods for improving functional vascular integrity, cellular survival and reducing apoptosis after an ischemic episode in the brain |
| 05/25/2011 | EP1868994B1 Sulfonylpyrroles as histone deacetylase inhibitors |
| 05/25/2011 | EP1781294B1 Composition for improved bioavailability and enhanced brain delivery of 5,5-diphenyl barbituric acid |